This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Renal Cell Carcinoma
and you are
over 18
years old
Phase
-
The phase for this study is not defined.
Show me locations

The purpose

The investigators hypothesize everolimus toxicities are linked to pharmacokinetic variabilities of everolimus. Thus, early detection of clinical or biological risk factors will lead to personalized dosage treatment and permit a better tolerance without altering efficacy.

Provided treatments

  • Other: Blood sample
Tris trial is registered with FDA with number: NCT01598038. The sponsor of the trial is Centre Francois Baclesse and it is looking for 41 volunteers for the current phase.
Official trial title:
Relation Between Safety Endpoints and Everolimus Trough Blood Level in Advanced Renal Cell Carcinoma